Abstract:Among the various risky complications of liver cirrhosis, refractory ascites is associated with poor survival of cirrhotics and persistently worsens their quality of life (QOL). Major clinical guidelines worldwide define refractory ascites as ascites that cannot be managed by medical therapy either because of a lack of response to maximum doses of diuretics or because patients develop complications related to diuretic therapy that preclude the use of an effective dose of diuretics. Due to the difficulty in receiving a liver transplantation (LT), the ultimate solution for refractory ascites, most cirrhotic patients have selected the palliative therapy such as repeated serial paracentesis, transjugular intrahepatic portosystemic shunt, or peritoneovenous shunt to improve their QOL. During the past several decades, new interventions and methodologies, such as indwelling peritoneal catheter, peritoneal-urinary drainage, and cell-free and concentrated ascites reinfusion therapy, have been introduced. In addition, new medical treatments with vasoconstrictors or vasopressin V2 receptor antagonists have been proposed. Both the benefits and risks of these old and new modalities have been extensively studied in relation to the pathophysiological changes in ascites formation. Although the best solution for refractory ascites is to eliminate hepatic failure either by LT or by causal treatment, the selection of the best palliative therapy for individual patients is of utmost importance, aiming at achieving the longest possible, comfortable life. This review briefly summarizes the changing landscape of variable treatment modalities for cirrhotic patients with refractory ascites, aiming at clarifying their possibilities and limitations. Evolving issues with regard to the impact of gut-derived systemic and local infection on the clinical course of cirrhotic patients have paved the way for the development of a new gut microbiome-based therapeutics. Thus, it should be further investigated whether the early therapeutic approach to gut dysbiosis provides a better solution for the management of cirrhotic ascites.

Progress on Diagnosis and Treatment of Refractoryascites in Patients with Hepatic Failure

[Research Advances in Diagnosis and Treatment of Liver Failure in 2016].

Liver Transplantation in Patients with Liver Failure: Twenty Years of Experience from China

Clinical and Neuroimaging Characteristics and Prognosis of Patients with Hepatic Myelopathy and Hepatic Encephalopathy

Current management of refractory ascites in patients with cirrhosis

An update on the pathogenesis and clinical management of cirrhosis with refractory ascites

Focus on Pharmaceutical Care and Progress in Management of Patients with Liver Cirrhosis and Ascites

Management of refractory cirrhotic ascites: challenges and solutions

Acute-on-chronic Liver Failure in Chronic Hepatitis B: an Update.

Artificial Liver Support System in China: a Review over the Last 30 Years.

Ascites, refractory ascites and hyponatremia in cirrhosis

Hotspots and Management Strategies for Liver Failure Diagnosis and Treatment

Study of Ascitic-Concentrated Bacteria-Filtered Intravenous Re-Transfusion (ABR) to Treat Patients with Peritonitis of Schistosoma Cirrhosis

Successful treatment of refractory ascites in a patient with liver cirrhosis combined with hepatic artery-portal vein malformation: A case report

Recent developments in the management of ascites in cirrhosis

Recent insights into contributing factors in the pathogenesis of cirrhotic ascites

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Plasma Exchange-Centered Artificial Liver Support System in Hepatitis B Virus-Related Acute-on-chronic Liver Failure: a Nationwide Prospective Multicenter Study in China.

Research progress on the role of probiotics in acute liver failure

Double Ascites Ultrafiltration and Reinfusion into Abdominal Cavity of Hepatocirrhosis Patients with Refractory Ascites Combined with Spontaneous Bacterial Peritonitis

The rate of change in clinical indicators can predict the progression of hepatitis B virus-related acute-on-chronic preliver failure